Health Care Delivery

Insurance plans offered through the Affordable Care Act are placing fewer drugs on the specialty tier of formularies than they were 2 years prior, according to a new study from Avalere.

Oral anticancer agents are being launched at significantly higher prices compared with a decade ago, which can prove a barrier to patient access, according to a new analysis published in JAMA Oncology.

What We’re Reading, April 29, 2016: While sales of Gilead's Harvoni drop, NY state attorney's decision could be good news for the company; and the FDA faces a lawsuit from a consumer advocacy group.